Product category: Neurological diagnosis, apparatus and instruments
Tbit™ Blood Testing Platform
World's First Nanowire Biosensing Platform for concussion and other TBI Delivers objective results in less than 90 seconds, identifying TBI and reducing unnecessary CT scans for concussion. Point-of-care platform to detect and measure a panel of protein biomarkers released into the bloodstream after a Traumatic Brain Injury.
BioDirection, Inc. is a privately-held medical device company developing novel and rapid point-of care products for the objective management of concussion and other traumatic brain injuries (TBI).
Tbit™ System BioDirections first product is called the Tbit™ system. The Tbit™ system is the worlds first multiplexing platform utilizing patented biosensing nanowire technology that can detect and measure very low concentrations of "biomarker" proteins released from the brain after a concussion or other traumatic brain injury.
Objective Diagnosis in 90 Seconds This breakthrough platform technology delivers objective information to aid in the diagnosis of a concussion from just a single drop of blood in less than 90 seconds. Additionally, this technology provides emergency responders with new actionable data that can help in reducing unnecessary head CT scans, thereby saving time and costs while eliminating unnecessary radiation exposure to the patient.
Intellectual Property BioDirection holds a large intellectual property portfolio with broad filings in both the U.S. and in key foreign jurisdictions for the use of Nano biosensors in the field of brain injury. The extensive Harvard University generated intellectual property portfolio was invented by Dr. Charles Lieber, a recognized pioneer in the field of Nanowire technology.